| atomoxetine / Generic mfg. |
2005-001909-25: Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders(Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder and ADHD). |
|
|
| | 2 | 30 | Europe | Strattera, Capsule* | | Open treatment with atomoxetine for 10 weeks:•Week 1: 0,5 mg/kg/day in 1 or 2 doses. •Week 2 – 6: 1,2 mg/kg/day i 1 or 2 doses.•Week 6 – 8: Significant improvements: Continue on 1,2 mg/kg/day in 1 or 2 doses. Not improved: 1,4 mg/kg/day in 1 or 2 doses. There will be medical consultations at week 1, 2, 4, 6 and 10 weeks. Patients or parents can contact the doctor in between if needed. | | | | |
2015-001916-37: The neuropsychological features of aggressive behaviour in children and adolescents with diagnosis of Conduct Disorder or Oppositional Defiant Disorder (CD/ODD) Caratteristiche neuropsicologiche del comportamento aggressivo in bambini e adolescenti con diagnosi di Disturbo della Condotta o Disturbo Oppositivo Provocatorio |
|
|
| | 2 | 160 | Europe | Film-coated tablet, Tablet, Capsule, hard, Modified-release capsule, hard, Risperdal, Abilify, Strattera, Medikinet | RADBOUD UNIVERSITY MEDICAL CENTER, 7PQ Unione Europea | Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD) Aggressività in bambini e adolescenti affetti da Disturbo della Condotta (CD) o Disturbo Oppositivo Provocatorio (ODD), Aggressive behavior in children and adolescents with a psychiatric diagnosis of Conduct Disorder or Oppositional Defiant Disorder Aggressività in bambini e adolescenti con diagnosi psichiatrica di Disturbo della Condotta o Disturbo Oppositivo Provocatorio, Psychiatry and Psychology [F] - Psychological processes [F02] | | | | |
NCT00485628: Safety Study in Outpatient Japanese Children With ADHD |
|
|
| Completed | 2 | 37 | Japan | Atomoxetine Hydrochloride | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 10/03 | | |
NCT00167297: Atomoxetine for the Treatment of Cannabis Dependence |
|
|
| Completed | 2 | 16 | US | Atomoxetine | National Institute on Drug Abuse (NIDA), University of Pennsylvania | Cannabis Dependence | 07/05 | 07/05 | | |
NCT00174226: Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar |
|
|
| Completed | 2 | 241 | US | Atomoxetine, Buspirone | Pfizer | Attention Deficit Disorder With Hyperactivity | | 01/06 | | |
NCT00142961: Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 2 | 2 | US | Atomoxetine, placebo | New York State Psychiatric Institute, National Institute on Drug Abuse (NIDA) | Attention Deficit Disorder With Hyperactivity, Marijuana Abuse | 01/07 | 01/07 | | |
Atom, NCT00218543: oxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 20 | US | Atomoxetine | New York State Psychiatric Institute, National Institute on Drug Abuse (NIDA) | Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders | 03/07 | 03/07 | | |
NCT00029614: Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD |
|
|
| Completed | 2 | 24 | US | Atomoxetine | University of Pittsburgh, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Substance Use Disorders, Attention Deficit Hyperactivity Disorder | | 07/07 | | |
NCT00429091: A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 243 | US | ABT-894, atomoxetine, placebo | Abbott | Attention-Deficit/Hyperactivity Disorder, ADHD | 08/07 | | | |
NCT00420498: Effects of Atomoxetine on Cognitive Function in Schizophrenia |
|
|
| Completed | 2 | 12 | US | Atomoxetine (Strattera™) | Yale University, National Alliance for Research on Schizophrenia and Depression | Schizophrenia, Cognition, Smoking | | 09/07 | | |
| Completed | 2 | 20 | US | atomoxetine, Strattera, Matching Placebo, Sugar pill | University of Iowa, Eli Lilly and Company | Huntington Disease, Chorea | 02/08 | 02/08 | | |
NCT00530335: Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 45 | Japan | Atomoxetine, LY139603, Strattera | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 04/08 | 04/08 | | |
NCT00528697: A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 278 | US | ABT-089, atomoxetine, placebo | AbbVie (prior sponsor, Abbott) | Attention-Deficit/Hyperactivity Disorder | 04/08 | 04/08 | | |
NCT00360269: Atomoxetine Treatment for ADHD and Marijuana Dependence |
|
|
| Completed | 2 | 38 | US | Atomoxetine, Strattera, Motivational enhancement therapy, MET, Placebo, Sugar pill | Medical University of South Carolina, National Institute on Drug Abuse (NIDA) | Marijuana Abuse, Attention Deficit Disorder With Hyperactivity | 06/08 | 06/08 | | |
NCT00636818: Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 45 | RoW | Atomoxetine, LY139603, Strattera | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 09/08 | 10/08 | | |
NCT00880217: A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 430 | US | Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Attention Deficit Hyperactivity Disorder | 01/10 | 01/10 | | |
NCT00617201: Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial |
|
|
| Completed | 2 | 50 | US | atomoxetine, Straterra, placebo | Sharon Walsh, Eli Lilly and Company, National Institute on Drug Abuse (NIDA) | Substance Abuse | 08/11 | 08/11 | | |
Atomoxetine, NCT00548327: The Effects of on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype |
|
|
| Terminated | 2 | 11 | US | Atomoxetine, Strattera, Functional magnetic resonance imaging, Neuropsychological Testing, Neuropsychiatric testing, Placebo | National Institute of Mental Health (NIMH) | Schizophrenia, Memory Disorders, Cognition Disorders | 11/11 | 11/11 | | |
| Completed | 2 | 12 | NA | Atomoxetine, Strattera, Placebo, Sham | Lumy Sawaki | Atomoxetine Hydrochloride, Placebos | 12/12 | 12/14 | | |
NCT01738191: Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) |
|
|
| Completed | 2 | 30 | US | Atomoxetine, Strattera, Placebo | Medical University of South Carolina, Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease, Cognitive Impairment | 08/14 | 08/14 | | |
NCT01863251: Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia |
|
|
| Completed | 2 | 90 | RoW | Atomoxetine, Stratera | Yale University | Opiate Dependence, Stimulant Dependence | 08/14 | 09/14 | | |
NCT01522404: Effects of Atomoxetine in Mild Cognitive Impairment |
|
|
| Completed | 2 | 39 | US | Atomoxetine, Strattera, Primary Outcome Measure, Placebo, Inactive compound | Emory University, National Institute on Aging (NIA) | Mild Cognitive Impairment | 10/17 | 06/18 | | |
NCT01399827: Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits |
|
|
| Completed | 2 | 2 | US | ADHD Medication, Methylphenidate extended release (OROS-MPH), Concerta, Vyvanse, Dextroamphetamine, Adderall, Mixed Amphetamine Salts, Amphetamine, Strattera, Atomoxetine, Focalin, Dexmethylphenidate, Omega-3 Fatty Acids, Nordic Natural EPA Xtra | Massachusetts General Hospital | Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR) | 11/17 | 11/17 | | |
POST6, NCT02874937: A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope |
|
|
| Completed | 2 | 57 | Canada | Atomoxetine, Apo-atomoxetine, Matching Placebo, Placebo | University of Calgary | Syncope, Vasovagal | 11/17 | 01/18 | | |
| Completed | 2 | 57 | Canada | Atomoxetine, Strattera, Placebo | University of Calgary, Cardiac Arrhythmia Network of Canada | Vasovagal Syncope | 01/18 | 03/18 | | |
NCT03091400: Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS) |
|
|
| Completed | 2 | 11 | US | Atomoxetine, Strattera (Eli Lilly), Placebo | Icahn School of Medicine at Mount Sinai | Memory Disorders, Multiple Sclerosis | 06/18 | 06/18 | | |
NCT03324581: The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder |
|
|
| Completed | 2 | 239 | US | OPC-64005, Atomoxetine, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Adult Attention Deficit Hyperactivity Disorder | 10/18 | 10/18 | | |
NCT00562055: Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder. |
|
|
| Withdrawn | 2 | 0 | NA | Atomoxetine, PNU-165442G; [S,S]-reboxetine | Pfizer | Attention Deficit Hyperactivity Disorder | | | | |
2019-004455-36: Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients. |
|
|
| Not yet recruiting | 2 | 45 | Europe | Capsule, STRATTERA® (Atomoxetine) | CHU DE POITIERS, CHU POITIERS | High impulsive Tourette’s syndrome patients, Tourette’s syndrome, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 2 | 48 | US | Atomoxetine, strattera, Placebo, non active medication | Vanderbilt University Medical Center, NYU Langone Health | Neurogenic Orthostatic Hypotension | 05/21 | 06/23 | | |
NCT04580394: Crossover Trial of AD109 in Obstructive Sleep Apnea |
|
|
| Completed | 2 | 60 | US | AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test, DSST | Apnimed | Obstructive Sleep Apnea | 05/21 | 05/21 | | |
| Not yet recruiting | 2 | 260 | NA | AD109 (atomoxetine/aroxybutynin), Atomoxetine Hydrochloride, Placebo | Apnimed | Obstructive Sleep Apnea (OSA) | 04/22 | 04/22 | | |
NCT04905979: Trial of AD113 and Atomoxetine in OSA Patients With Hypertension |
|
|
| Completed | 2 | 21 | US | AD113, Atomoxetine | Apnimed | Obstructive Sleep Apnea, Hypertension | 01/23 | 05/23 | | |
NCT04565288: Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine |
|
|
| Active, not recruiting | 2 | 42 | US | Atomoxetine, Strattera, Placebo | Brown University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 09/24 | 09/24 | | |
NCT04354103: Atomoxetine in Patients With Tourette's Syndrome |
|
|
| Terminated | 2 | 5 | Europe | Atomoxetine | Poitiers University Hospital | Tourette Syndrome | 01/24 | 01/24 | | |
| Not yet recruiting | 2 | 60 | NA | Atomoxetine, Black Seed Oil Cap/Tab | Ain Shams University | ADHD | 10/25 | 10/25 | | |
NCT00089869: A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia |
|
|
| Completed | 1/2 | | US | olanzapine, atomoxetine, placebo | Eli Lilly and Company | Schizophrenia | | | | |
| Completed | 1/2 | 10 | US | Placebo, Atomoxetine | Yale University, US Department of Veterans Affairs | Stress | 08/07 | 09/09 | | |
| Completed | 1/2 | 10 | US | Atomoxetine | Yale University, National Institute on Drug Abuse (NIDA) | Physiological Stress | 08/07 | 09/09 | | |
NCT00573859: The Reinforcing Mechanisms of Smoking in Adult ADHD |
|
|
| Completed | 1/2 | 27 | US | ADHD medication, Dextroamphetamine, Amphetamine mixed salts, Atomoxetine, O-Methylphenidate, Lisdexamfetamine, Placebo | University of California, Irvine | ADHD | 06/10 | 06/10 | | |
NCT01557569: Clinical Efficacy of Atomoxetine for Methamphetamine Dependence |
|
|
| Completed | 1/2 | 20 | US | Atomoxetine, strattera, placebo, "sugar pill" | University of Arkansas, National Institute on Drug Abuse (NIDA) | Methamphetamine Dependence | 06/15 | 07/15 | | |
NCT02046551: Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers |
|
|
| Withdrawn | 1/2 | 0 | US | Atomoxetine, Strattera, Placebo | Yale University, VA Office of Research and Development | Nicotine Dependence | 02/17 | 02/17 | | |
| Completed | 1/2 | 15 | US | Dosing 1: Atomoxetine, 40mg or 80 mg Atomoxetine, AD313, atomoxetine dronabinol | Apnimed | Obstructive Sleep Apnea | 04/22 | 04/22 | | |
| Recruiting | 1/2 | 70 | US | Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone | Brigham and Women's Hospital | Obstructive Sleep Apnea | 10/26 | 10/26 | | |
| Recruiting | 1/2 | 18 | US | Placebo oral capsule, Atomoxetine Oral Capsule [Strattera], DAW2020 Oral Capsule | Brigham and Women's Hospital | Obstructive Sleep Apnea | 06/24 | 06/24 | | |
| Active, not recruiting | 1/2 | 150 | US | Acetazolamide, Diamox, Atomoxetine, Strattera, NO Drug, Clonidine, Catapres, Entacapone, Comtan, Entacapone & Propranolol, Inderal, Atomoxetine & Propranolol, Indomethacin, Indocin, Mecamylamine, inversine, Isosorbide Dinitrate, Isordil, Melatonin, Midodrine, pro-amatine, Modafinil, provigil, Octreotide, sandostatin, Placebo, Propranolol, Modafinil & Propranolol, Provigil, Sertraline, Zoloft, IV Saline, NaCl solution (0.9%), Drinking Water, Breathing Device, memantine, Namenda, Abdominal binder | Satish R. Raj, National Center for Advancing Translational Sciences (NCATS) | Tachycardia, Chronic Orthostatic Intolerance | 12/25 | 12/25 | | |
